131i-mip-1095
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 19, 2017 (NCT03030885)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Glutamate carboxypeptidase IIRadiodepletion
FOLH1 radiodepletion
Chemistry & pharmacology
- Payload
- 131-iodine
Oral
No
Parenteral
No
Topical
No
Also known as
- 131i-mip-1095
- 131i-mip-1095
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03030885 | Phase 1 | Jan 19, 2017 | Cornell University, Progenics |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Progenics | For profit | 1 | 0 | 1 | 2017 |
2 organizations
Page 1 / 1